Exelixis Inc. (NASDAQ:EXEL) is without doubt one of the finest progress shares to purchase for the subsequent 2 years. On August 29, Exelixis Inc. introduced the appointment of Dana T. Aftab, Ph.D., as its new Govt Vice President, Analysis & Improvement. On this position, he’ll oversee all points of the corporate’s drug discovery, translational analysis, product improvement, and medical affairs.
Dr. Aftab has been with Exelixis for greater than 25 years, having joined the corporate in 1998. Most lately, he served as Govt Vice President, Discovery & Translational Analysis & Chief Scientific Officer since December 2022. He has been a key determine within the discovery and improvement of the corporate’s flagship medication, CABOMETYX (cabozantinib), which is a number one tyrosine kinase inhibitor within the US for treating superior renal cell carcinoma and superior neuroendocrine tumors.
This appointment follows the departure of Amy Peterson, M.D., who had served as Govt Vice President, Product Improvement & Medical Affairs, and Chief Medical Officer since August 2023.
Exelixis Inc. (NASDAQ:EXEL) is an oncology firm that discovers, develops, and commercializes new medicines for difficult-to-treat cancers within the US.
Whereas we acknowledge the potential of EXEL as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back danger. In the event you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially printed at Insider Monkey.